RT Journal Article
SR Electronic
T1 Prostaglandin D<sub>2</sub>-Induced Eosinophilic Airway Inflammation Is Mediated by CRTH2 Receptor
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 954
OP 960
DO 10.1124/jpet.104.078212
VO 312
IS 3
A1 Yoshiki Shiraishi
A1 Koichiro Asano
A1 Takeshi Nakajima
A1 Tsuyoshi Oguma
A1 Yusuke Suzuki
A1 Tetsuya Shiomi
A1 Koichi Sayama
A1 Kyoko Niimi
A1 Misa Wakaki
A1 Junko Kagyo
A1 Eiji Ikeda
A1 Hiroyuki Hirai
A1 Kazuhiro Yamaguchi
A1 Akitoshi Ishizaka
YR 2005
UL http://jpet.aspetjournals.org/content/312/3/954.abstract
AB Mast cell-derived prostaglandin D2 (PGD2) is one of the essential modulators of eosinophilic airway inflammation in asthma and allergic rhinitis. Two G protein-coupled receptors for PGD2, prostaglandin D2 receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), are both expressed on the surface of eosinophils, and CRTH2 has been demonstrated to mediate PGD2-induced eosinophil mobilization in vitro. However, it has not yet been determined whether PGD2 and its receptors mediate in vivo eosinophil trafficking into the airways or other organs. We demonstrated that intratracheal administration of PGD2 in rats pretreated with systemic interleukin-5 (IL-5) injection induced marked airway eosinophilia, determined by the differential counts of cells in bronchoalveolar lavage (BAL) fluid and lung histology, within 2 h. Systemic IL-5 alone significantly increased the number of eosinophils in the peripheral blood but showed no effect on airway eosinophilia. Three CRTH2-specific agonists (13,14-dihydro-15-keto-PGD2, 11-deoxy-11-methylene-15-keto-PGD2, and indomethacin) demonstrated equivalent induction of BAL eosinophilia to that of PGD2, but a DP agonist (BW 245C [5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)-hydantoin]) or a thromboxane A2 receptor (TP) agonist ([1S-1α,2β(5Z), 3α(1E,3R*),4α)]-7-[3-(3-hydroxy-4-(4′-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid) showed no effect. PGD2 or CRTH2 agonist-induced BAL eosinophilia was almost completely inhibited by pretreatment with a CRTH2/TP antagonist, ramatroban [BAY-u3405; (+)-(3R)-3-(4-fluorobenzenesulfonamido)-1,2,3,4-tetra-hydrocarbazole-9-propionic acid], whereas a TP-specific antagonist, SQ29,548 (5-heptenoic, 7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]-hept-2-yl]-[1S-[1α,2α(Z),3α,4α]]), or a DP-specific antagonist, BW A868C [3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexy-2-hydroxyethylamino)-hydantoin], did not inhibit the effects of PGD2. These results suggest that CRTH2 plays a significant role in the eosinophil trafficking from the bloodstream into the airways in PGD2-related airway inflammation. The American Society for Pharmacology and Experimental Therapeutics